Aptar Pharma Expands Pulmonary Delivery Capabilities with Pulmotree Acquisition

October 27, 2026 - 00:50

Aptar Pharma, a division of AptarGroup Inc., has acquired Pulmotree, a life sciences company based in Munich, Germany. The move strengthens the company's position in pulmonary drug delivery technology and broadens its portfolio of solutions for respiratory treatments.

Pulmotree specializes in the development of inhalation technologies, including nebulizer systems designed for precise and efficient drug delivery to the lungs. The company's expertise complements Aptar Pharma's existing offerings in nasal and pulmonary delivery, creating a more comprehensive platform for pharmaceutical partners working on respiratory therapies.

The acquisition reflects growing demand for advanced inhalation devices as pharmaceutical companies continue to develop treatments for conditions such as asthma, chronic obstructive pulmonary disease, and other respiratory disorders. By bringing Pulmotree's technology and capabilities in-house, Aptar Pharma aims to accelerate innovation and provide integrated solutions from early development through commercialization.

Financial terms of the deal were not disclosed. The transaction is expected to support Aptar Pharma's long-term growth strategy in the prescription drug delivery market, where device performance and patient usability are increasingly critical factors in product success. The company said the integration of Pulmotree's team and technology will enhance its ability to serve customers across Europe and globally.